Stay updated with breaking news from Recent Pipeline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high...
23.03.2023 - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for ...
RUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2... | March 23, 2023
13.09.2022 - Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth ...
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30,...